Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

What Was Tested

Researchers studied Enalapril and Losartan in this randomized controlled trial publication.

Therefore, the researchers compared the renal and hemodynamic effects of specific intervention in the renin-angiotensin system by blockade of the angiotensin II subtype-1 receptor to the effect of ACE inhibition.

Who Took Part

According to the abstract, 16 patients were involved.

By PubMed's age tags, the people studied were adults, both men and women.

A randomized, double-blind, cross-over trial was performed in 16 type 1 diabetic patients (10 men), age 42 +/- 2 years (mean +/- SEM).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The patients were allocated by chance, so the Enalapril group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Enalapril.

The comparison arm used a placebo, so changes seen with Enalapril could be set against what happens without it.

Each person switched between Enalapril and the comparison at some point, usually with a gap in between.

At the end of each period, albuminuria, 24-hour blood pressure, and glomerular filtration rate (GFR) were determined.

What Was Measured

The subject headings attached to it are Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Enalapril and Glomerular Filtration Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Enalapril and Losartan in 16 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (Kidney international), a journal based in United States.

More context: all human trials.